Critical Survey: Parallax Health Sciences (OTCMKTS:PRLX) vs. iSpecimen (NASDAQ:ISPC)

Parallax Health Sciences (OTCMKTS:PRLX) and iSpecimen (NASDAQ:ISPC) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Parallax Health Sciences and iSpecimen, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Parallax Health Sciences	0	0	0	0	0.00
iSpecimen	1	0	0	0	1.00

Given Parallax Health Sciences’ higher probable upside, research analysts plainly believe Parallax Health Sciences is more favorable than iSpecimen.

Profitability

This table compares Parallax Health Sciences and iSpecimen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Parallax Health Sciences	N/A	N/A	N/A
iSpecimen	-1,080.16%	-584.65%	-142.48%

Earnings & Valuation

This table compares Parallax Health Sciences and iSpecimen”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Parallax Health Sciences	N/A	N/A	N/A	N/A	N/A
iSpecimen	$1.03 million	3.33	-$10.49 million	($56.44)	-0.04

Parallax Health Sciences has higher earnings, but lower revenue than iSpecimen.

Institutional and Insider Ownership

13.6% of iSpecimen shares are owned by institutional investors. 12.2% of iSpecimen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

About Parallax Health Sciences

Parallax Health Sciences, Inc. is an integrated digital healthcare company. It is engaged in the provision of personalized patient care through remote healthcare services, behavioral health systems, and Point-of-Care diagnostic testing. The firm operates through the following segments: Remote Patient Monitoring, Behavioral Health Systems, and Corporate. The Remote Patient Monitoring segment offers a technology platform that includes a complete remote patient care delivery system through PHM. The Behavioral Health Systems segment includes the intellectual property, Reliable Evidence-Based Outcomes Optimization Technologies, through its wholly-owned subsidiary, Parallax Behavioral Health, Inc. The Corporate segment consists of management and administrative services. The company was founded on July 6, 2005 and is headquartered in Los Angeles, CA.

About iSpecimen

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.